title: Method to our madness or madness in our methods? Pitfalls in trial methodology.
authors.forename: Mark N
authors.initials: MN
authors.lastname: Levine
authors.forename: Rosalyn
authors.initials: R
authors.lastname: Juergens
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000077192:Adenocarcinoma of Lung; D000418:Albumins / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D000074324:Ipilimumab; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage*; D011799:Quinazolines / Q000008:administration & dosage*; D012907:Smoking / Q000009:adverse effects*; D012997:Solvents / Q000737:chemistry*
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D000911:Antibodies, Monoclonal; D000074324:Ipilimumab; D011799:Quinazolines; D012997:Solvents; D016190:Carboplatin; D000069347:Erlotinib Hydrochloride; D017239:Paclitaxel